|
|||||
|
|
Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis |
|
| Institution: | 2. Eli Lilly and Company, Indianapolis, Indiana (during the conduct of the study) and Novartis, East Hanover, New Jersey;3. Lilly France, Suresnes, Cedex, France;4. Eli Lilly and Company, Indianapolis, Indiana;5. University Hospital, Basel, Switzerland |
| Abstract: | |
| Keywords: | Pemetrexed Survival Toxicity Non-small cell lung cancer |
| 本文献已被 ScienceDirect 等数据库收录！ | |